Report Description Table of Contents HSDD Treatment Market: Non-Hormonal Therapies and Digital Access Expand Women’s Sexual Health Care The Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market was valued at USD 725 million in 2025 and is projected to reach USD 1.17 billion by 2032, expanding at a CAGR of 7.1% during 2026–2032, according to Strategic Market Research. HSDD is defined by persistently reduced sexual desire accompanied by significant personal distress and differs from temporary changes in libido caused by stress, relationship factors, medication use, or other underlying health conditions. The condition affects approximately 8%–10% of adult women globally and in the United States, representing a substantial untreated patient population. Based on a 10% prevalence rate among adult women, HSDD affects approximately 13.5 million women in the United States and nearly 380 million women worldwide, while around 6 million premenopausal U.S. women experience persistent low desire associated with distress. The treatment landscape is currently dominated by pharmacological therapies, supported by complementary psychological and behavioral interventions such as cognitive behavioral therapy, mindfulness-based approaches, sex therapy, and relationship counseling. Among approved drug therapies, Addyi (flibanserin) from Sprout Pharmaceuticals remains the leading daily oral non-hormonal treatment for acquired, generalized HSDD. Its expanded eligibility among women younger than 65 years, including selected postmenopausal patients, has increased the potential addressable population. Vyleesi (bremelanotide) provides an alternative on-demand injectable treatment approach for premenopausal women seeking episodic therapy. While its dosing flexibility offers differentiation from daily oral therapy, tolerability remains a key adoption challenge. Clinical studies reported nausea in approximately 40% of treated patients, with around 8% discontinuing treatment due to adverse effects, influencing repeat usage and broader prescription adoption. Overall, the HSDD treatment market is evolving from an underrecognized women’s health condition into a structured therapeutic category supported by approved medicines, digital healthcare access, and increasing clinical awareness. Future market growth will depend on improving diagnosis rates, expanding treatment accessibility, developing therapies with better efficacy and tolerability profiles, and addressing the large gap between affected women and those currently receiving medical care. Key Report Takeaways—Non-Hormonal Medicines Lead as Online Dispensing Accelerates By Therapy Type Non-Hormonal Agents account for an estimated 48% market share, equivalent to USD 348.00 million in 2025 revenue, with a projected CAGR of 8.5% during 2026–2032. Hormonal Therapies represent 24% of the market, generating USD 174.00 million in 2025, with a projected CAGR of 7.0% during 2026–2032. Other Off-Label Pharmacological Therapies contribute 6%, corresponding to USD 43.50 million in 2025 revenue, and are projected to expand at a CAGR of 5.0% during 2026–2032. Psychological and Behavioral Therapies hold 22% market share, equivalent to USD 159.50 million in 2025, with a projected CAGR of 5.6% during 2026–2032. By Route of Administration Oral Therapies represent 68% of pharmaceutical revenue, reaching USD 384.54 million in 2025, with a projected CAGR of 8.0% during 2026–2032. Parenteral/Injectable Therapies account for 12%, generating USD 67.86 million in 2025 revenue, and are projected to grow at a CAGR of 9.0% during 2026–2032. Topical/Transdermal Therapies contribute 20%, equivalent to USD 113.10 million in 2025, with a projected CAGR of 6.5% during 2026–2032. By Distribution Channel Hospital Pharmacies account for 15% of pharmaceutical revenue, corresponding to USD 84.83 million in 2025, with a projected CAGR of 5.0% during 2026–2032. Retail and Drugstore Pharmacies hold 50%, generating USD 282.75 million in 2025 revenue, with a projected CAGR of 6.5% during 2026–2032. Online and Mail-Order Pharmacies represent 35%, equivalent to USD 197.93 million in 2025, and are projected to expand at a CAGR of 10.5% during 2026–2032. By Geography North America accounts for an estimated 60% of global revenue, equivalent to USD 435.00 million in 2025, with a projected CAGR of 6.5% during 2026–2032. Europe represents 21% market share, generating USD 152.25 million in 2025 revenue, and is projected to expand at a CAGR of 7.2% during 2026–2032. Asia Pacific contributes 12%, corresponding to USD 87.00 million in 2025, with a projected CAGR of 10.1% during 2026–2032. Latin America holds 4% market share, equivalent to USD 29.00 million in 2025 revenue, with a projected CAGR of 8.0% during 2026–2032. Middle East and Africa account for 3%, generating USD 21.75 million in 2025, and are projected to grow at a CAGR of 7.8% during 2026–2032. Revenue Leadership and Growth Frontiers Across HSDD Treatment Therapy Mix—Non-Hormonal Agents Set the Revenue and Growth Pace Revenue and Growth Leader: Non-Hormonal Agents Non-hormonal agents accounted for 48% of the HSDD treatment market, generating USD 348.00 million in 2025 revenue, and are projected to expand at an 8.5% CAGR during 2026–2032 to reach USD 616.01 million. Growth is supported by increasing adoption of centrally acting therapies such as flibanserin and bremelanotide, which regulate dopamine, norepinephrine, serotonin, and melanocortin pathways associated with sexual desire. Growing preference for non-estrogen-based treatments and wider awareness of FDA-approved options further support segment expansion. Administration Pathways—Oral Therapies Lead While Injectables Expand Faster Revenue Leader: Oral Therapies Oral therapies represent 68% of pharmaceutical revenue, accounting for USD 384.54 million in 2025 and are expected to reach USD 659.03 million by 2032, expanding at an 8.0% CAGR and contributing an additional USD 274.49 million in revenue growth. These therapies primarily act on central nervous system pathways by modulating neurotransmitter activity involved in sexual desire regulation. Flibanserin, an FDA-approved daily oral treatment for premenopausal women with acquired generalized HSDD, remains the key marketed option, while off-label therapies such as bupropion are also used in selected cases. Growth is supported by increasing awareness, diagnosis, and demand for non-invasive treatment options, although safety considerations such as drug interactions and alcohol restrictions influence adoption. Growth Leader: Parenteral/Injectable Therapies Injectable therapies represent 12% of pharmaceutical revenue, or USD 67.86 million in 2025, and are modeled to expand at 9.0% CAGR to USD 124.05 million by 2032. Vyleesi provides an as-needed alternative to daily medication, but its usage pattern makes revenue dependent on both patient retention and dose frequency. Nausea affected 40% of treated patients, required anti-emetic treatment in 13%, and caused discontinuation in 8%, highlighting a direct limitation on repeat demand. Dispensing Channels—Retail Maintains Scale While Online Access Accelerates Revenue Leader: Retail and Drugstore Pharmacies Retail and drugstore pharmacies represent a major distribution channel, accounting for 50% of pharmaceutical revenue, equivalent to USD 282.75 million in 2025, and are projected to reach USD 439.39 million by 2032 at a 6.5% CAGR. These pharmacies manage approximately 45% of HSDD and female sexual dysfunction treatment distribution, providing convenient access to therapies such as flibanserin (Addyi) and bremelanotide (Vyleesi). Their role extends beyond dispensing to include medication reviews, interaction monitoring, privacy-focused patient support, and counseling on dosage, side effects, and treatment adherence. Growth Leader: Online and Mail-Order Pharmacies Online and mail-order pharmacies represent a significant distribution channel for HSDD treatments, accounting for 35% of pharmaceutical revenue and generating USD 197.93 million in 2025. This segment is projected to expand at a 10.5% CAGR, reaching approximately USD 398.14 million by 2032. Growth is supported by rising demand for discreet access, improved medication availability, digital consultations, and adherence support for patients managing a sensitive and often underdiagnosed condition. Regional Outlook—North America Leads While Asia Pacific Records Faster Growth Revenue Leader: North America North America remains the leading regional market for Hypoactive Sexual Desire Disorder (HSDD) treatments, accounting for 60% of global revenue, equivalent to USD 435.00 million in 2025. The region is expected to reach USD 675.98 million by 2032, adding approximately USD 240.98 million at a 6.5% CAGR. Growth is supported by advanced healthcare infrastructure, availability of FDA-approved therapies, expanding diagnosis rates, and increasing awareness of women’s sexual health conditions. The presence of established pharmaceutical players and favorable treatment adoption patterns further strengthens regional demand. Growth Leader: Asia Pacific Asia Pacific holds an illustrative 12% market share, corresponding to USD 87.00 million in 2025. Its assumed 10.1% CAGR takes revenue to USD 170.62 million by 2032, an increase of approximately 96%. Despite faster percentage growth, its USD 83.62 million revenue addition remains substantially below North America’s. This forecast is conditional on country-specific treatment access and diagnosis expanding; available evidence does not independently establish Asia Pacific as the fastest-growing region. Clinical Applications—Patient Eligibility Defines the Addressable Treatment Population Core Approved Population: Acquired, Generalized HSDD in Premenopausal Women Premenopausal HSDD is an established application for both daily oral flibanserin (Addyi) and on-demand injectable bremelanotide (Vyleesi). Their indications target distressing low desire that developed after previously normal desire and occurs across situations or partners. This creates distinct prescription opportunities based on treatment preference, but low desire caused by another medical condition, relationship problems, or medication use falls outside these approved indications. Expanded Oral-Therapy Population: HSDD in Postmenopausal Women Under 65 Postmenopausal treatment represents an expanded application for Addyi, whose current indication includes eligible women younger than 65. Its clinical evidence includes 902 postmenopausal women under 65, within a broader program of more than 3,200 participants across four six-month trials. This expansion gives clinicians an approved oral option for an additional patient group and creates prescription potential within menopause care. Vyleesi remains outside the approved postmenopausal indication. Non-Drug Care Pathway: Psychological and Behavioral Management Cognitive behavioral therapy, mindfulness, and sex or relationship counseling address psychological and interpersonal factors identified during assessment. These services generate consultation and session-based revenue rather than pharmacy sales. They may accompany medication in appropriate patients, while low desire primarily attributable to relationship difficulties or psychiatric illness requires a different treatment approach. Consequently, counseling demand should be measured separately from the population eligible for approved HSDD medicines. Selective Hormonal Pathway: Selected Hormonal Treatment Testosterone therapy is used for selected postmenopausal patients, with approval status and prescribing practices varying by jurisdiction. Its market contribution should include only treatment attributable to HSDD rather than total testosterone or menopause-therapy sales. Estrogen used for vaginal discomfort and other menopausal symptoms should likewise be distinguished from direct HSDD treatment. This separation prevents broader menopause spending from overstating the market. Adjacent Care Pathway: Assessment of Medication-Related Low Desire Medication review is relevant when reduced desire follows antidepressant use or another prescription. Such care can generate assessment and follow-up demand, but medication-induced sexual dysfunction is excluded from the approved indications of Addyi and Vyleesi. Revenue from managing these cases should therefore be treated as adjacent sexual-health care unless the report explicitly includes it within its scope. Competitive Landscape—Sprout Leads Daily Oral Therapy as Cosette Differentiates Through On-Demand Dosing Sprout Pharmaceuticals—Expanded Eligibility Broadens Addyi’s Prescription Base Sprout Pharmaceuticals markets Addyi (flibanserin), the daily oral HSDD treatment first approved in 2015. Its current indication includes eligible women younger than 65, including postmenopausal women, expanding its prescription opportunity beyond the original premenopausal population. Addyi’s clinical evidence includes four six-month trials involving more than 3,200 women, including 902 postmenopausal participants under 65. The broader indication gives Sprout an opportunity to expand prescribing within menopause care. Sprout also competes through treatment access. Addyi’s advertised cash price is USD 149 per month through PHILRx, with home delivery, while eligible patients with insurance coverage may pay as little as USD 20 monthly, subject to restrictions. These programs connect prescribing with fulfillment and can reduce financial barriers to starting treatment. However, sustained revenue depends on symptom improvement and continued refills. Cosette Pharmaceuticals—On-Demand Vyleesi Creates a Differentiated Treatment Path Cosette Pharmaceuticals owns Vyleesi (bremelanotide), the FDA-approved, as-needed injectable treatment for acquired, generalized HSDD in premenopausal women. Cosette acquired the product from Palatin in December 2023 for USD 12 million upfront, with up to USD 159 million in contingent sales-based milestones. The transaction added an approved sexual-health medicine to Cosette’s women’s-health portfolio, with most potential consideration tied to future commercial performance. Vyleesi differentiates Cosette through an on-demand option for patients who prefer treatment around anticipated sexual activity. Its commercial challenge is treatment persistence: nausea occurred in 40% of treated patients and caused 8% to discontinue. These findings make tolerability and repeat use central to the product’s revenue potential. Pipeline and Historical Participants Shaping Future Competition Arletta Pharma Solutions, formerly Freya: Develops the investigational testosterone–sildenafil combination Lybrido and announced a Phase II dose-response study in August 2025, positioning it as a potential future competitor. Palatin Technologies: Developed Vyleesi and sold it to Cosette in 2023, retaining potential milestone-related economic interests rather than its former direct commercialization role. AMAG Pharmaceuticals: Previously commercialized Vyleesi in North America, but its agreement with Palatin ended in 2020, making its role historical rather than that of a current HSDD product owner. Analyst Commentary—Treatment Persistence Will Define HSDD Market Leadership The hypoactive sexual desire disorder treatment market’s next competitive opportunity lies in therapies that improve desire and reduce associated distress while remaining acceptable for continued use. Based on the illustrative segment estimates, non-hormonal agents account for 48% of revenue and carry an 8.5% growth forecast, placing treatment differentiation at the center of competition. Broader patient eligibility can expand prescription opportunities, but daily oral convenience or on-demand dosing alone will not ensure sustained adoption. Affordability, meaningful symptom improvement, and tolerability will determine repeat use. New entrants will need to demonstrate advantages that translate into better treatment persistence and justify switching from existing options. HSDD Treatment Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 725 Million Revenue Forecast in 2032 USD 1.17 Billion Overall Growth Rate CAGR of 7.1% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Therapy Type, By Route of Administration, By Distribution Channel, By Clinical Application, By Geography By Therapy Type Non-Hormonal Agents, Hormonal Therapies, Other Off-Label Pharmacological Therapies, Psychological and Behavioral Therapies By Route of Administration Oral Therapies, Parenteral/Injectable Therapies, Topical/Transdermal Therapies By Distribution Channel Hospital Pharmacies, Retail and Drugstore Pharmacies, Online and Mail-Order Pharmacies By Clinical Application Acquired, Generalized HSDD in Premenopausal Women; HSDD in Postmenopausal Women Under 65; Psychological and Behavioral Management; Selected Hormonal Treatment; Assessment of Medication-Related Low Desire By Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Large untreated patient population, improving clinical recognition, expanded eligibility for oral non-hormonal treatment, availability of on-demand injectable therapy, increasing digital healthcare access, discreet online dispensing, and demand for therapies with improved efficacy and tolerability Customization Option Available upon request Frequently Asked Question About This Report Q1. What keeps the addressable patient pool largely untapped in this market? A1. HSDD affects an estimated 8%–10% of adult women, but diagnosis and treatment remain limited. Many patients do not discuss persistent low desire with healthcare providers or may have symptoms attributed to other causes. Better clinical recognition could move more eligible patients into structured care. Q2. Why do non-hormonal agents hold the strongest position across the industry? A2. Addyi and Vyleesi provide approved treatment options without relying on estrogen-based therapy. Non-hormonal agents held an estimated 48% share worth USD 348.00 million in 2025. The segment is projected to grow at an 8.5% CAGR through 2032. Q3. How does Addyi’s expanded eligibility change this market? A3. Addyi can now serve eligible women younger than 65, including selected postmenopausal patients. Its clinical program included more than 3,200 women, including 902 postmenopausal participants. The broader indication expands prescription opportunities beyond the original premenopausal population. Q4. What limits the commercial potential of injectable treatment in the industry? A4. Vyleesi offers on-demand dosing for premenopausal women who do not want a daily medicine. However, nausea affected about 40% of treated patients and caused 8% to discontinue therapy. Tolerability and repeat use will therefore determine whether injectable revenue can sustain its projected 9.0% CAGR. Q5. Why are online pharmacies gaining share in this market? A5. Digital consultations and home delivery provide greater privacy for patients seeking care for a sensitive condition. Online and mail-order pharmacies represented 35% of pharmaceutical revenue and generated USD 197.93 million in 2025. The channel is projected to grow at a 10.5% CAGR. Q6. Which regional dynamics will shape the industry’s next growth phase? A6. North America leads with an estimated 60% share due to approved therapies and stronger diagnosis infrastructure. Asia Pacific is projected to grow faster at a 10.1% CAGR. This outlook depends on wider treatment availability, improved awareness, and country-specific reimbursement development. Sources: DailyMed—Addyi (Flibanserin) Prescribing Information FDA—Vyleesi (Bremelanotide) Prescribing Information DailyMed—Current Vyleesi Prescribing Information ISSWSH—Expert Consensus Review of HSDD Epidemiology, Diagnosis, and Treatment NCBI—Treatment of Hypoactive Sexual Desire Disorder Among Women NCBI—Management of Hypoactive Sexual Desire Disorder in Women PubMed—Bremelanotide RECONNECT Phase III Trials PubMed—SNOWDROP Trial of Flibanserin in Postmenopausal Women PubMed—Systematic Review and Meta-Analysis of Flibanserin AP News—FDA Expands Addyi Approval to Postmenopausal Women Under 65 Addyi—Treatment Access, Telehealth, and Patient Pricing Vyleesi—Official Healthcare Professional Product and Safety Information ClinicalTrials.gov—Lybrido Clinical Development Study Arletta Pharma Solutions—Lybrido Development Program Cosette Pharmaceuticals—Official Vyleesi Product Information Fierce Pharma—Palatin’s Sale of Vyleesi to Cosette Pharmaceuticals Table of Contents - Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Therapy Type, Route of Administration, Distribution Channel, Clinical Application, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Therapy Type, Route of Administration, Distribution Channel, Clinical Application, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Therapy Type, Route of Administration, Distribution Channel, and Clinical Application Investment Opportunities in the Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Non-Hormonal Therapies, On-Demand Treatment, Digital Healthcare Access, Online and Mail-Order Dispensing, Psychological and Behavioral Management, and Expanded Women's Sexual Health Services Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of HSDD Treatment in Women's Sexual Health, Diagnosis, Treatment Access, and Long-Term Care Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory, Clinical, Safety, and Patient Access Factors Role of Non-Hormonal Medicines, Oral Therapies, Injectable Therapies, Digital Healthcare Access, and Online Dispensing in Market Expansion Treatment Persistence, Diagnosis Gaps, Affordability, Tolerability, and Discreet Access Trends in HSDD Care Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapy Type: Non-Hormonal Agents Hormonal Therapies Other Off-Label Pharmacological Therapies Psychological and Behavioral Therapies Market Analysis by Route of Administration: Oral Therapies Parenteral/Injectable Therapies Topical/Transdermal Therapies Market Analysis by Distribution Channel: Hospital Pharmacies Retail and Drugstore Pharmacies Online and Mail-Order Pharmacies Market Analysis by Clinical Application: Acquired, Generalized HSDD in Premenopausal Women HSDD in Postmenopausal Women Under 65 Psychological and Behavioral Management Selected Hormonal Treatment Assessment of Medication-Related Low Desire Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapy Type, Route of Administration, Distribution Channel, and Clinical Application Country-Level Breakdown: United States Canada Mexico Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapy Type, Route of Administration, Distribution Channel, and Clinical Application Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapy Type, Route of Administration, Distribution Channel, and Clinical Application Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapy Type, Route of Administration, Distribution Channel, and Clinical Application Country-Level Breakdown: Brazil Rest of Latin America Middle East & Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapy Type, Route of Administration, Distribution Channel, and Clinical Application Country-Level Breakdown: Saudi Arabia UAE South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Sprout Pharmaceuticals Cosette Pharmaceuticals Arletta Pharma Solutions Palatin Technologies AMAG Pharmaceuticals Daré Bioscience, Inc. S1 Biopharma, Inc. Vella Bioscience Strategic Science & Technologies, LLC Competitive Landscape and Strategic Insights Benchmarking Based on Product Indication, Treatment Modality, Clinical Development Stage, Route of Administration, Patient Eligibility, Distribution Access, Digital Healthcare Integration, and Women's Health Portfolio Presence Therapeutic Differentiation Across Daily Oral and On-Demand Treatment Pathways Non-Hormonal Treatment Positioning and Expanded Patient Eligibility Analysis Affordability, Tolerability, Treatment Persistence, and Prescription Access Strategy Analysis Online, Mail-Order, and Digital Healthcare Access Strategy Analysis Pipeline and Historical Participant Analysis Across HSDD and Female Sexual Health Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Therapy Type, Route of Administration, Distribution Channel, Clinical Application, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading HSDD Treatment Vendors Regulatory, Clinical, Safety, and Patient Access Analysis Technology and Treatment Adoption Trends Across Oral Therapies, Parenteral/Injectable Therapies, Topical/Transdermal Therapies, Digital Healthcare Access, and Online Dispensing List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Therapy Type, Route of Administration, Distribution Channel, and Clinical Application (2025 vs. 2032) Global HSDD Treatment Ecosystem and Women's Sexual Health Care Pathway Analysis